Systemic Lupus Erythematous (SLE) Drugs Market Share 2021 Growth Challenges, Opportunities and Future Trends 2027
The global systemic lupus erythematous (SLE) drugs market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). Systemic Lupus Erythematous (SLE) is a chronic autoimmune disease that causes the immune system to attack healthy body tissue. In SLE, the body immune system can affect any part of the body, such as joints, organs, eyes, skin, among others. The major factor for the growth of the market during the forecast period is the high prevalence of autoimmune diseases, particularly systemic lupus erythematous (SLE).
According to the Lupus
Foundation of America, 1.5 million Americans, and at least five million people
have a form of lupus globally. Additionally, lupus strikes mostly women of
childbearing age. However, men, children, and teenagers can also develop lupus.
Further, as per the same source, almost 90% of people living with lupus are
women and most people develop the disease between the ages of 15-44. Apart from
this, there are 16,000 new cases of lupus every year.
To Request a Sample of our Report on Systemic Lupus
Erythematous (SLE) Drugs Market: https://www.omrglobal.com/request-sample/systemic-lupus-erythematous-sle-drugs-market
Some major key players in the market include
Bristol-Myers Squibb Co., GlaxoSmithKline plc, and Sanofi S.A., among others.
The market players are contributing significantly to the growth of the market
by the adoption of various strategies including mergers & acquisitions,
geographical expansion, partnerships and collaborations, and new product
launches, to stay competitive in the market. For instance, in December 2020,
GlaxoSmithKline plc received approval for BENLYSTA (belimumab) by the FDA for
the treatment of adult patients with active lupus nephritis. Lupus nephritis is
a serious inflammation of the kidneys caused by systemic lupus erythematosus (SLE).
Market Coverage
• The
market number available for – 2020-2027
• Base
year- 2020
• Forecast
period- 2021-2027
• Segment
Covered-
·
By Product
·
By Distribution Channel
• Regions
Covered-
·
North America
·
Europe
·
Asia-Pacific
·
Rest of the World
•
Competitive Landscape-Bristol-Myers
Squibb Co., GlaxoSmithKline plc,and Sanofi S.A., among others.
(Get 15% Discount on Buying this Report)
A
full Report of Systemic Lupus Erythematous (SLE) Drugs Market is Available
at: https://www.omrglobal.com/industry-reports/systemic-lupus-erythematous-sle-drugs-market
Global Systemic Lupus Erythematous (SLE) Drugs Market
Report by Segment
By Product
• Corticosteroids
• Non-Steroidal
Anti-inflammatory Drugs (NSAIDs)
• Anti-Inflammatories
• Disease-Modifying
Anti-Rheumatic Drugs (DMARDs)
• Antimalarials
• BLyS-specific
Inhibitors or Monoclonal Antibodies (MAbS)
• Immunosuppressive
Agents/Immune Modulators
• Anticoagulants
By Distribution Channel
• Hospital
Pharmacies
• Drug
Stores
• Online
Drug Stores
Global Systemic Lupus Erythematous (SLE) Drugs Market
Report by Region
North America
·
United States
·
Canada
Europe
·
UK
·
Germany
·
Spain
·
France
·
Italy
·
Rest of Europe
Asia-Pacific
·
India
·
China
·
Japan
·
South Korea
·
Rest of APAC
Rest of the World
·
Latin America
·
Middle East & Africa
Reasons to buy from us –
1. We cover more than
15 major industries, further segmented into more than 90 sectors.
2. More than 120
countries are for analysis.
3. Over 100+ paid
data sources mined for investigation.
4. Our expert
research analysts answer all your questions before and after purchasing your
report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company
known for its crisp and concise reports. The company is equipped with an
experienced team of analysts and consultants. OMR offers quality syndicated
research reports, customized research reports, consulting and other
research-based services.
Media
Contact:
Company
Name: Orion Market Research
Contact
Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact
no: +91 7803040404
Comments
Post a Comment